The drug ent-verticilide reduced A-fib incidence and duration in an animal model, suggesting it may be a viable therapeutic option.
A technique to characterize all variants in genes associated with arrhythmia could improve the ability to identify and preemptively treat individuals at risk for sudden cardiac death.
Vanderbilt University Medical Center investigators have used high-throughput robotic technology to rapidly study and classify variations in a gene linked to heart rhythm disorders and cardiac conditions.
Björn Knollmann, M.D., Ph.D., has been named director of the newly formed Vanderbilt Center for Arrhythmia Research and Therapeutics (VanCART).
Accessibility Tools